Day: June 14, 2024

Progressive Reports May 2024 Results

Written by Customer Service on June 14, 2024. Posted in Earnings Releases And Operating Results.

MAYFIELD VILLAGE, OHIO, June 14, 2024 (GLOBE NEWSWIRE) — The Progressive Corporation (NYSE:PGR) today reported the following results for the month ended May 31, 2024: May(millions, except per share amounts and ratios; unaudited) 2024Net premiums written $ 5,975.1Net premiums earned $ 5,857.5Net income $ 235.7Per share available to common shareholders $ 0.40Total pretax net realized gains (losses) on securities $ 117.6Combined ratio – current year 100.4 – prior year month 99.0Average diluted equivalent common shares 587.4In October 2023, we converted our monthly accounting closing calendar to align with the Gregorian calendar. We do not expect that this change will have a material impact on our reported quarterly and annual underwriting results but it may impact our year-over-year...

Aktsiaselts Infortar signed an agreement for selling a shareholding at subsidiary

Written by Customer Service on June 14, 2024. Posted in Public Companies.

On June 14, 2024, Aktsiaselts Infortar and Apteegikaubanduse Hulgimüük OÜ signed a share purchase agreement for selling 80% shareholding in the subsidiary Farmatar OÜ. This transaction marks Infortar exit from the wholesale of pharmaceuticals and pharmacy goods business segment. Following the transaction, Apteegikaubanduse Hulgimüük OÜ will become the new owner of the 80% shareholding in Farmatar OÜ. The transaction is not treated as a transaction beyond everyday economic activities or a transaction of a significant importance, nor as a transaction with related persons, within the meaning of the “Requirements for Issuers” part of the NASDAQ Tallinn Stock Exchange rules. The transaction does not have a significant impact on Aktsiaselts Infortar’s activities. The members of the Supervisory Board and the Management Board...

Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market

Written by Customer Service on June 14, 2024. Posted in Public Companies.

LONDON, June 14, 2024 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the pricing of an underwritten offering of 12,531,300 of its American Depositary Shares (“ADSs”). Each ADS is being sold at a price of $3.99 per ADS in an underwritten registered direct offering priced at-the-market under Nasdaq rules. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $50.0 million. Each ADS represents five ordinary shares of Mereo. The net proceeds of this offering are expected to be used to fund the setrusumab program, including supply and pre-launch activities in Europe, and for working capital and other general corporate...

Subsea7 awarded a contract for the Bittern field in the UK North Sea

Written by Customer Service on June 14, 2024. Posted in Public Companies.

Luxembourg – 14 June 2024 – Subsea7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced the award of a sizeable1 contract by Dana Petroleum (E&P) Limited, for the Bittern field development, located approximately 190km east of Aberdeen in the UK Central North Sea, at a water depth of 90 metres. The contract scope includes project management, engineering, procurement, construction and installation (EPCI) of a 22km 12” water injection pipeline. Subsea7’s scope also includes associated subsea structures and tie-ins at the Triton Floating Production Storage & Offloading (FPSO) vessel and the Bittern field. Project management and engineering work will commence immediately in Aberdeen. The offshore activities are scheduled for Q3 2025. Steve Wisely, Senior Vice President of UK and Global Inspection, Repair and Maintenance, Subsea7,...

Medicare Issues Final Coverage Determination for kidneyintelX.dkd

Written by Customer Service on June 14, 2024. Posted in Public Companies.

Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage LONDON and NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that on June 13, 2024 Medicare issued a final Local Coverage Determination (“LCD”) for the Company’s kidneyintelX.dkd testing. The final LCD can be accessed at LCD – KidneyIntelX and KidneyIntelX.dkd Testing (L39726) (cms.gov), and is effective for dates of service on or after August 1, 2024. The established Medicare price for kidneyintelX.dkd is $950 per test. Distinct CPT Codes (Common Procedural Terminology Codes) have been established for kidneyintelX.dkd and is published in CMS’ 2024 Clinical Lab Fee Schedule. The LCD specifies...

Flagship Communities Real Estate Investment Trust Announces June 2024 Cash Distribution

Written by Customer Service on June 14, 2024. Posted in Dividend Reports And Estimates.

Not for distribution to U.S. newswire services or dissemination in the United States. TORONTO, June 14, 2024 (GLOBE NEWSWIRE) — Flagship Communities Real Estate Investment Trust (the “REIT”) (TSX:MHC.U; MHC.UN) announced today a cash distribution of US$0.0492 per REIT unit for the month of June 2024, representing US$0.59 per REIT unit on an annual basis. Payment will be made on or about July 15, 2024, to unitholders of record as of the close of business on June 28, 2024. Distributions paid to Canadian unitholders (and other non-U.S. unitholders) generally will be subject to U.S. withholding tax. Unitholders should consult their own tax advisors for advice with respect to the tax consequences of receiving a distribution from the REIT in their own circumstances. About Flagship Communities Real Estate Investment Trust Flagship Communities...

Auction result of Treasury Bills – RIKV 24 0821 – RIKV 24 1218

Written by Customer Service on June 14, 2024. Posted in Public Companies.

Series RIKV 24 0821 RIKV 24 1218Settlement Date 06/19/2024 06/19/2024Total Amount Allocated (MM) 25,755 30,561All Bids Awarded At (Price / Simple interest) 98.382 / 9.398 95.440 / 9.451Total Number of Bids Received 14 25Total Amount of All Bids Received (MM) 27,355 39,561Total Number of Successful Bids 12 22Number of Bids Allocated in Full 12 22Lowest Price / Highest Simple Interest Allocated 98.382 / 9.398 95.440 / 9.451Highest Price / Lowest Simple Interest Allocated 98.426 / 9.138 95.602 / 9.100Lowest Price / Highest Simple Interest Allocated in Full 98.382 / 9.398 95.440 / 9.451Weighted Average of Successful Bids (Price/Simple Interest) 98.391 / 9.345 95.481 / 9.362Best Bid (Price / Simple Interest) 98.426 / 9.138 95.602 / 9.100Worst Bid (Price / Simple Interest) 98.280 / 10.001 95.394 / 9.551Weighted...

Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress

Written by Customer Service on June 14, 2024. Posted in Public Companies.

TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational Drugs in AMLTUS Monotherapy and TUS+VEN Doublet Therapy Active in Difficult-to-treat Genetic Subgroups, FLT3 Wildtype AMLTUS Shown to Target VEN Resistance Mechanisms and Retain Activity on VEN-Resistant AML Cells in Preclinical StudyTUS+VEN+Azacitidine (AZA) Triplet Trial to Treat Newly Diagnosed AML Patients; Clinical Sites Being ActivatedSAN DIEGO and TORONTO, June 14, 2024 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies,...

Intellia Therapeutics Names Brian Goff to its Board of Directors

Written by Customer Service on June 14, 2024. Posted in Public Companies.

CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Brian Goff to its board of directors. “We are very pleased to welcome Brian to our board of directors. Brian’s extensive global commercialization experience, coupled with his track record of success leading rare disease product launches, will be invaluable to Intellia as we commercialize our first CRISPR-based gene editing therapies for people with life-threatening diseases,” said Intellia President and Chief Executive Officer John Leonard, M.D. “We look forward to leveraging Brian’s first-hand experience to guide us through the exciting evolution from late-stage clinical development to a commercial...

Brixton Metals Appoints Patrick Highsmith to its Board of Directors

Written by Customer Service on June 14, 2024. Posted in Public Companies.

VANCOUVER, British Columbia, June 14, 2024 (GLOBE NEWSWIRE) — Brixton Metals Corporation (TSX-V: BBB, OTCQB: BBBXF) (the “Company” or “Brixton”) is pleased to announce the appointment of Mr. Patrick Highsmith as a director and Chair of the Company’s Compensation Committee, effective June 11, 2024. Mr. Highsmith has more than 30 years of international experience including operational, exploration and business development roles with major companies such as Newmont Mining, BHP, Rio Tinto, and Fortescue Metals Group. He also has co-founded, and/or acted as a director or senior executive in several junior companies. His junior company pedigree includes Canadian listed companies such as: Lithium One, Bellhaven Copper & Gold, Pure Energy Minerals, Champion Electric Metals, and FireFox Gold, for whom he is co-founder and chairman...

Day: June 14, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals